Cohen & Steers, Inc. (CNS) reported preliminary assets under management (AUM) of $80.5 billion as of May 31, 2024. This reflected growth of 4.3% from the prior month's level. The increase was mainly attributable to a market appreciation of $3.6 billion. This was partly offset by net outflows of $93 million and distributions of $150 million. Cohen & Steers recorded total institutional accounts of $32.1 billion at the end of May 2024, jumping 4.8% from the April 2024-end. Of the total institutional accounts, ...

About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore. Assets Under Management (unaudited) SOURCE Cohen & Steers, Inc. NEW YORK, June 10, 2024 /PRNewswire/ -- Cohen ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical company specializing in developing treatments for central nervous system [CNS] conditions. The company has two successful FDA-approved commercial franchises, Nuplazid (pimavanserin), approved in 2016 for Parkinson's disease psychosis, and Daybue (trofinetide), approved in March 2023 for Rett syndrome. Despite a setback with a failed clinical trial for a new indication for Nuplazid as a treatment for schizophrenia, the company stands strong wit ...

Core Insights - Ventyx Biosciences announced positive preclinical data for its NLRP3 inhibitor VTX3232, showing improvements in body weight, systemic inflammatory biomarkers, and cardiometabolic parameters in diet-induced obesity (DIO) mice [1][2] Study Findings - In DIO Study 1, VTX3232 monotherapy resulted in reduced body weight, body fat content, food consumption, liver triglycerides, and liver fat deposits, along with improvements in insulin resistance and cardiometabolic parameters [2][8] - DIO Study 2 demonstrated that the combination of VTX3232 with the GLP-1 receptor agonist semaglutide produced additive effects, leading to greater reductions in body weight, liver steatosis, and metabolic parameters compared to either treatment alone [2][8] - Systemic inflammatory biomarkers such as IL-1β, IL-6, and fibrinogen were significantly reduced in the plasma of DIO mice treated with VTX3232, with further reductions observed in the combination therapy group [8] Future Plans - The company plans to initiate a Phase 2a trial of VTX3232 in participants with obesity and cardiovascular risk factors in the second half of 2024 [2] - Comprehensive results from the studies will be submitted for future publication or presentation in a scientific forum [5]

NEW YORK, June 3, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today that an affiliate of Cohen & Steers Capital Management, Inc. ("Cohen & Steers") and DLC Management ("DLC"), an owner and operator of open-air shopping centers in the U.S., have jointly acquired a two-property open-air shopping center complex in Fayetteville, Arkansas. The acquisition is comprised of two centers, Spring Creek Centre and Steele Crossing, and encompasses 403,000 square feet of owned retail space. The center ...

NEW YORK, May 15, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today additional pending changes to its Realty Majors Indexes, effective as of the close of business on May 17, 2024. LondonMetric Property Plc replaces LXI REIT Plc in the Cohen & Steers Global Realty Majors Portfolio Index (GRM) and Cohen & Steers International Realty Majors Portfolio Index (IRP). The changes result from the former's acquisition of the latter. Additional previously announced changes to the indexes are listed ...

NEW YORK, May 13, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today a change to its Realty Majors Portfolio Index (RMP) capitalization policy. Currently, individual index constituent capitalization weights are limited to a maximum of 8%. Effective as of close of business on May 17, 2024, constituent weightings will now be subject to an additional adjustment if the sum of the constituents that individually have a weight greater than 4.5% exceeds 45% of the total index. If the new rule is ...

Cohen & Steers, Inc. (CNS) reported preliminary assets under management (AUM) of $77.2 billion as of Apr 30, 2024. This reflected a decline of 4.9% from the prior month's level.The decrease was due to market depreciation of $3.9 billion, net outflows of $74 million and distributions of $151 million.Cohen & Steers recorded total institutional accounts of $30.6 billion at the end of April 2024, falling 5.5% from the March 2024-end level. Of the total institutional accounts, advisory accounts were $17.4 billio ...

NEW YORK, May 8, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $77.2 billion as of April 30, 2024, a decrease of $4.1 billion from assets under management of $81.2 billion at March 31, 2024. The decrease was due to market depreciation of $3.9 billion, net outflows of $74 million and distributions of $151 million. Assets Under Management (unaudited)   ($ in millions) AUM Net Market AUM By investment vehicle: 3/31/2024 Flows Deprec ...

SECURITIES AND EXCHANGE COMMISSION FORM 10-Q For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO 1166 Avenue of the Americas, New York, NY 10036 (Address of Principal Executive Offices and Zip Code) (212) 832-3232 (Registrant's Telephone Number, Including Area Code) ________________ Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant: ...